Promising Clinical Trial Results for Personalized Cancer Vaccine
Wyndham Wilson, MD, PhD of the National Cancer Institute (NCI) and a member of the Lymphoma Research Foundation's (LRF's) Scientific Advisory Board (SAB) presented promising results from a Phase II BiovaxID trial at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO). The trial found that BiovaxID following rituximab combination therapy strongly correlated with overall survival and time-to-next treatment benefits in patients with mantle cell lymphoma (MCL), a type of non-Hodgkin lymphoma (NHL).
The study suggests that the vaccine induces tumor-specific T-cell responses which ultimately results in slowing tumor growth and improved survival with minimal toxicity. The trial found that over 10 years, patients with a high degree of T-cell response to vaccination experienced approximately 75% overall survival compared to 25% survival for patients with a low degree of T-cell response. Results are published in an article in the June 2012 issue of Genetic Engineering & Biotechnology News titled Autologous Immunotherapy Updates at ASCO.
In addition, follicular lymphoma (FL), another type of NHL, may also be treated by the BiovaxID at some time in the future – it's maker is currently seeking approval for BiovaxID in the European Union and Canada and they are also preparing a pre-filing meeting with the US Food and Drug Administration (FDA).